ONCT Oncternal Therapeutics
- 8.2900
- +0.0400+0.48%
Oncternal Therapeutics News
Express News | Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 197.87% HC Wainwright & Co. $30 → $28 Maintains Buy 01/29/2024 219.15% HC Wainwright & Co. $2 →
Express News | Oncternal Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $28 From $30
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
IRVINE, Calif., April 11, 2024 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans Keirstea
Oncternal Therapeutics(ONCT.US) Director Buys US$27,654.57 in Common Stock
$Oncternal Therapeutics(ONCT.US)$ Director Wills Robert James purchased 3,086 shares of common stock on Apr 8, 2024 at an average price of $8.9613 for a total value of $27,654.57.Source: Announcement
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
Oncternal Therapeutics(ONCT.US) Director Buys US$58,602.37 in Common Stock
$Oncternal Therapeutics(ONCT.US)$ Director Wills Robert James purchased 6,914 shares of Common Stock on Mar 28, 2024 at an average price of $8.4759 for a total value of $58,602.37.Source: Announcement
Oncternal Participating in Virtual Fireside Chat With Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Oncternal Therapeutics Files for Mixed Shelf Offering
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Q4 2023 Oncternal Therapeutics Inc Earnings Call
Earnings Call Summary | Oncternal Therapeutics(ONCT.US) Q4 2023 Earnings Conference
The following is a summary of the Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript:Financial Performance:Oncternal Therapeutics' Q4 2023 revenue came from grants that totaled $0.3
Recap: Oncternal Therapeutics Q4 Earnings
Oncternal Therapeutics (NASDAQ:ONCT) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsOncternal Therapeutics mi
Oncternal Therapeutics GAAP EPS of -$3.11 Misses by $0.03, Revenue of $0.3M Beats by $0.16M
Oncternal Therapeutics 4Q Loss $9.16M >ONCT
Oncternal Therapeutics 4Q Loss $9.16M >ONCT
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte
Analysis
Price Target
No Data
